药明康德(02359.HK)完成配售6820.54万股H股 净筹72.9亿港元
格隆汇 8 月 5日丨药明康德(02359.HK)宣布,已达成所有条件并于2020年8月5日完成配售。配售代理已根据配售协议的条款及条件按每股配售股份配售价108.0港元向不少于六名独立承配人成功配售合共6820.54万股配售股份。
配售的募集资金净额约为72.9亿港元,将按以下方式投入使用:(a)约35.0%用于并购,包括但不限于扩展集团于美国、欧洲及亚太区的业务;(b)约20.0%用于扩展集团海外业务;(c)约15.0%用于建设常熟研发一体化项目;(d)约10.0%用于偿还银行贷款及其他借款;及(e)剩余金额用于补充公司的营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.